The benzodiazepine receptor: Its development and its modulation by γ-aminobutyric acid

J. W. Regan, W. R. Roeske, H. I. Yamamura

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Evidence for the presence of benzodiazepine receptors in brain tissue recently has been described. To assess the physiological significance of these receptors, we have examined the ontogeny of [3H]flunitrazepam binding in homogenates of mouse brain. Specific [3H]flunitrazepam binding appears early in fetal development (11.0 fmol/mg of tissue at 17 days gestation). There is a rapid increase in the neonate: 23% of adult levels in the 1-day neonate, 47% in the 7-day neonate, 58% in the 15-day neonate and adult levels in the 21-day neonate. This development profile for [3H]flunitrazepam binding is similar to the development of the γ-aminobutyric acid (GABA) receptor. In washed membrane preparations, the dissociation constant (KD) of [3H]flunitrazepam binding can be increased (whole homogenate 0.69 nM; twice washed membranes, 1.17 nM). This effect may be due to the removal of endogenous GABA. The direct effects of exogenously applied GABA have been studied at different ages. From fetal to adult ages, GABA increased the affinity of [3H]flunitrazepam binding approximately 2-fold. At the same ages, the GABA antagonist, (+)-bicuculline, decreased the affinity of [3H]flunitrazepam binding. Kinetic analysis of [3H]flunitrazepam binding indicated that the changes in KD could be accounted for by changes in the rate constant of dissociation. We conclude that the benzodiazepine receptor in the mouse brain: develops rapidly in the neonatal period, can be modulated by GABA at all ages, and shows changes in affinity that can be explained by changes in the rate constant of dissociation.

Original languageEnglish (US)
Pages (from-to)137-143
Number of pages7
JournalJournal of Pharmacology and Experimental Therapeutics
Volume212
Issue number1
StatePublished - 1980

Fingerprint

Aminobutyrates
Flunitrazepam
GABA-A Receptors
gamma-Aminobutyric Acid
Brain
GABA Antagonists
GABA Receptors
Membranes
Bicuculline
Fetal Development
Pregnancy

ASJC Scopus subject areas

  • Pharmacology

Cite this

The benzodiazepine receptor : Its development and its modulation by γ-aminobutyric acid. / Regan, J. W.; Roeske, W. R.; Yamamura, H. I.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 212, No. 1, 1980, p. 137-143.

Research output: Contribution to journalArticle

@article{ba91ef237e1a4cd8bbd86729f94146cc,
title = "The benzodiazepine receptor: Its development and its modulation by γ-aminobutyric acid",
abstract = "Evidence for the presence of benzodiazepine receptors in brain tissue recently has been described. To assess the physiological significance of these receptors, we have examined the ontogeny of [3H]flunitrazepam binding in homogenates of mouse brain. Specific [3H]flunitrazepam binding appears early in fetal development (11.0 fmol/mg of tissue at 17 days gestation). There is a rapid increase in the neonate: 23{\%} of adult levels in the 1-day neonate, 47{\%} in the 7-day neonate, 58{\%} in the 15-day neonate and adult levels in the 21-day neonate. This development profile for [3H]flunitrazepam binding is similar to the development of the γ-aminobutyric acid (GABA) receptor. In washed membrane preparations, the dissociation constant (KD) of [3H]flunitrazepam binding can be increased (whole homogenate 0.69 nM; twice washed membranes, 1.17 nM). This effect may be due to the removal of endogenous GABA. The direct effects of exogenously applied GABA have been studied at different ages. From fetal to adult ages, GABA increased the affinity of [3H]flunitrazepam binding approximately 2-fold. At the same ages, the GABA antagonist, (+)-bicuculline, decreased the affinity of [3H]flunitrazepam binding. Kinetic analysis of [3H]flunitrazepam binding indicated that the changes in KD could be accounted for by changes in the rate constant of dissociation. We conclude that the benzodiazepine receptor in the mouse brain: develops rapidly in the neonatal period, can be modulated by GABA at all ages, and shows changes in affinity that can be explained by changes in the rate constant of dissociation.",
author = "Regan, {J. W.} and Roeske, {W. R.} and Yamamura, {H. I.}",
year = "1980",
language = "English (US)",
volume = "212",
pages = "137--143",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - The benzodiazepine receptor

T2 - Its development and its modulation by γ-aminobutyric acid

AU - Regan, J. W.

AU - Roeske, W. R.

AU - Yamamura, H. I.

PY - 1980

Y1 - 1980

N2 - Evidence for the presence of benzodiazepine receptors in brain tissue recently has been described. To assess the physiological significance of these receptors, we have examined the ontogeny of [3H]flunitrazepam binding in homogenates of mouse brain. Specific [3H]flunitrazepam binding appears early in fetal development (11.0 fmol/mg of tissue at 17 days gestation). There is a rapid increase in the neonate: 23% of adult levels in the 1-day neonate, 47% in the 7-day neonate, 58% in the 15-day neonate and adult levels in the 21-day neonate. This development profile for [3H]flunitrazepam binding is similar to the development of the γ-aminobutyric acid (GABA) receptor. In washed membrane preparations, the dissociation constant (KD) of [3H]flunitrazepam binding can be increased (whole homogenate 0.69 nM; twice washed membranes, 1.17 nM). This effect may be due to the removal of endogenous GABA. The direct effects of exogenously applied GABA have been studied at different ages. From fetal to adult ages, GABA increased the affinity of [3H]flunitrazepam binding approximately 2-fold. At the same ages, the GABA antagonist, (+)-bicuculline, decreased the affinity of [3H]flunitrazepam binding. Kinetic analysis of [3H]flunitrazepam binding indicated that the changes in KD could be accounted for by changes in the rate constant of dissociation. We conclude that the benzodiazepine receptor in the mouse brain: develops rapidly in the neonatal period, can be modulated by GABA at all ages, and shows changes in affinity that can be explained by changes in the rate constant of dissociation.

AB - Evidence for the presence of benzodiazepine receptors in brain tissue recently has been described. To assess the physiological significance of these receptors, we have examined the ontogeny of [3H]flunitrazepam binding in homogenates of mouse brain. Specific [3H]flunitrazepam binding appears early in fetal development (11.0 fmol/mg of tissue at 17 days gestation). There is a rapid increase in the neonate: 23% of adult levels in the 1-day neonate, 47% in the 7-day neonate, 58% in the 15-day neonate and adult levels in the 21-day neonate. This development profile for [3H]flunitrazepam binding is similar to the development of the γ-aminobutyric acid (GABA) receptor. In washed membrane preparations, the dissociation constant (KD) of [3H]flunitrazepam binding can be increased (whole homogenate 0.69 nM; twice washed membranes, 1.17 nM). This effect may be due to the removal of endogenous GABA. The direct effects of exogenously applied GABA have been studied at different ages. From fetal to adult ages, GABA increased the affinity of [3H]flunitrazepam binding approximately 2-fold. At the same ages, the GABA antagonist, (+)-bicuculline, decreased the affinity of [3H]flunitrazepam binding. Kinetic analysis of [3H]flunitrazepam binding indicated that the changes in KD could be accounted for by changes in the rate constant of dissociation. We conclude that the benzodiazepine receptor in the mouse brain: develops rapidly in the neonatal period, can be modulated by GABA at all ages, and shows changes in affinity that can be explained by changes in the rate constant of dissociation.

UR - http://www.scopus.com/inward/record.url?scp=0018877502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018877502&partnerID=8YFLogxK

M3 - Article

C2 - 7351621

AN - SCOPUS:0018877502

VL - 212

SP - 137

EP - 143

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 1

ER -